Integrating PI3 K/AKT/mTOR inhibitors with drugs that target alternative cancer stem cell–related pathways, epithelial–mesenchymal transition regulators, or the tumor microenvironment may enhance treatment effectiveness. This evidence concerns the gene MTOR and cancer.